Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Apr;11(4):472-8.
doi: 10.1007/s11605-006-0032-8.

The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings

Nir Lubezky  1 , Ur Metser, Ravit Geva, Richard Nakache, Einat Shmueli, Joseph M Klausner, Einat Even-Sapir, Arie Figer, Menahem Ben-Haim
Affiliations
Comparative Study

The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings

Nir Lubezky et al. J Gastrointest Surg. 2007 Apr.

Abstract

Background: Recent data confirmed the importance of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the selection of patients with colorectal hepatic metastases for surgery. Neoadjuvant chemotherapy before hepatic resection in selected cases may improve outcome. The influence of chemotherapy on the sensitivity of FDG-PET and CT in detecting liver metastases is not known.

Methods: Patients were assigned to either neoadjuvant treatment or immediate hepatic resection according to resectability, risk of recurrence, extrahepatic disease, and patient preference. Two-thirds of them underwent FDG-PET/CT before chemotherapy; all underwent preoperative contrast-enhanced CT and FDG-PET/CT. Those without extensive extrahepatic disease underwent open exploration and resection of all the metastases according to original imaging findings. Operative and pathological findings were compared to imaging results.

Results: Twenty-seven patients (33 lesions) underwent immediate hepatic resection (group 1), and 48 patients (122 lesions) received preoperative neoadjuvant chemotherapy (group 2). Sensitivity of FDG-PET and CT in detecting colorectal (CR) metastases was significantly higher in group 1 than in group 2 (FDG-PET: 93.3 vs 49%, P<0.0001; CT: 87.5 vs 65.3, P=0.038). CT had a higher sensitivity than FDG-PET in detecting CR metastases following neoadjuvant therapy (65.3 vs 49%, P<0.0001). Sensitivity of FDG-PET, but not of CT, was lower in group 2 patients whose chemotherapy included bevacizumab compared to patients who did not receive bevacizumab (39 vs 59%, P=0.068).

Conclusions: FDG-PET/CT sensitivity is lowered by neoadjuvant chemotherapy. CT is more sensitive than FDG-PET in detecting CR metastases following neoadjuvant therapy. Surgical decision-making requires information from multiple imaging modalities and pretreatment findings. Baseline FDG-PET and CT before neoadjuvant therapy are mandatory.

PubMed Disclaimer

References

    1. None
    2. Kemeny N, Fong Y. Treatment of liver metastases. Cancer Medicine. Baltimore: Williams and Wilkins, 1997, pp 1939–1954.
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC1353397', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1353397/'}, {'type': 'PubMed', 'value': '6703792', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/6703792/'}]}
    2. Fortner JG, Silva JS, Golbey RB, et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. 1. Treatment by hepatic resection. Ann Surg 1984;199:306–316. - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '6732473', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/6732473/'}]}
    2. Adson MA, Van Heerden JA, Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;11: 647–651. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '3526605', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/3526605/'}]}
    2. Hughes KS, Simon R, Soughourabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi institutional study of patterns of recurrence. Surgery 1986;100:278–284. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/BF00316981', 'is_inner': False, 'url': 'https://doi.org/10.1007/bf00316981'}, {'type': 'PubMed', 'value': '7740812', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/7740812/'}]}
    2. Scheele J, Strangl R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1985;19:59–71. - PubMed

Publication types

Substances